ACADStockAcadia Pharmaceuticals Inc
Verdicts genuinely change. Free email alert the moment ACAD's does — no target price to set, unlike a price alert.
Near limit Ratio screen, 3 of 7 decided standards passing. AAOIFI is within 3 points of its line. What would change it
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Trade plan
Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
Acadia Pharmaceuticals Inc (ACAD) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-12). See the full ratio breakdown and business-activity screen below for the reasoning.
This sits among 434 compliant Healthcare stocks we track. See compliant Healthcare stocks →
🕌 In-house Compliance Research
Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.
AAOIFI divides by the market cap: $3.2B as of 2026-11-18.
Business activity: cleared (no excluded categories detected)
AAOIFI Fail 2 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 2.27% | 30.00% | Pass(27.7pp buffer) |
| Interest-bearing investments | 30.84% | 30.00% | Fail(0.8pp over) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
Usmani Fail 3 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 4.00% | 33.00% | Pass(29.0pp buffer) |
| Interest-bearing investments | 54.42% | 33.00% | Fail(21.4pp over) |
| Non-liquid assets | 36.60% | at least 20.00% | Pass(16.6pp above the floor) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
MSCI Fail 2 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 4.00% | 33.33% | Pass(29.3pp buffer) |
| Cash + interest-bearing securities | 54.42% | 33.33% | Fail(21.1pp over) |
| Accounts receivable | 63.40% | 33.33% | Fail(30.1pp over) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
FTSE Fail 2 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.33% | Pass(33.3pp buffer) |
| Cash + interest-bearing securities | 54.42% | 33.33% | Fail(21.1pp over) |
| Accounts receivable | 63.40% | 50.00% | Fail(13.4pp over) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
Dow Jones Islamic Market Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 1.87% | 33.00% | Pass(31.1pp buffer) |
| Cash + interest-bearing securities | 25.36% | 33.00% | Pass(7.6pp buffer) |
| Accounts receivable | 4.18% | 33.00% | Pass(28.8pp buffer) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
S&P Shariah Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 1.96% | 33.00% | Pass(31.0pp buffer) |
| Cash + interest-bearing securities | 26.58% | 49.00% | Pass(22.4pp buffer) |
| Accounts receivable | 4.38% | 49.00% | Pass(44.6pp buffer) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
MSCI M-Series Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 1.96% | 33.33% | Pass(31.4pp buffer) |
| Cash + interest-bearing securities | 26.58% | 33.33% | Pass(6.8pp buffer) |
| Accounts receivable | 30.96% | 49.00% | Pass(18.0pp buffer) |
| Non-permissible income | 0.00% | 5.00% | Pass(5.0pp buffer) |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
How close is it to flipping?
Every current reading against its own line, closest first. A verdict is only as durable as that distance.
The numbers the ratios are built from
Read from ACAD's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | $1.1B | 2026-09-30 | RevenueFromContractWithCustomerExcludingAssessedTax |
| Interest-bearing debtShort and long-term borrowings | $0 | 2026-09-30 | no debt tag reported in 3+ years (treated as $0) |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | $976.4M | 2026-09-30 | CashAndCashEquivalentsAtCarryingValue, AvailableForSaleSecuritiesDebtSecuritiesCurrent |
| Total assetsBalance sheet total | $1.8B | 2026-09-30 | Assets |
| Market capDenominator for AAOIFI | $3.2B | live quote | price x shares |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | $3.5B | 756 trading days | closes x shares |
| 24-month average market capDenominator for Dow Jones Islamic Market | $3.7B | 504 trading days | closes x shares |
| Non-permissible revenueInterest and excluded income | $0 | 2026-09-30 | no interest-income tag reported in 3+ years (treated as $0) |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
Sources
Filing information. Balance sheet: Quarterly report (10-Q) filed 2026-11-05, period ended 2026-09-30. Income statement: Annual report (10-K) filed 2026-02-26, period ended 2026-09-30. Screened 2026-11-18.
-
Total assets$1.8B
Assets· period ended 2026-09-30 · 10-Q filed 2026-11-05 -
Interest-bearing debt$0
no debt tag reported in 3+ years (treated as $0)· balance sheet as of 2026-09-30 · no filing link for this figure -
Cash and interest-bearing securities$976.4M
CashAndCashEquivalentsAtCarryingValue$322.4M · period ended 2026-09-30 · 10-Q filed 2026-11-05AvailableForSaleSecuritiesDebtSecuritiesCurrent$654.1M · period ended 2026-09-30 · 10-Q filed 2026-11-05 -
Receivables$161.0M
AccountsReceivableNetCurrent· period ended 2026-09-30 · 10-Q filed 2026-11-05 -
Revenue$1.1B
RevenueFromContractWithCustomerExcludingAssessedTax· period ended 2025-12-31 · 10-K filed 2026-02-26 -
Interest income (non-permissible)$0
no interest-income tag reported in 3+ years (treated as $0)· income statement as of 2026-09-30 · no filing link for this figure -
Market cap$3.2BMarket quote passed in by the screen (Finnhub company profile; Yahoo Finance where Finnhub has none), 2026-11-18 · not a filing figure, so no link
5 reported values cited from 2 SEC filings, read from SEC's XBRL company facts when this symbol was screened. A link opens the filing's index on EDGAR.
What changed, and when
Verdict history for ACAD. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
- 2026-11-16 Pass → Fail filing re-screen
Tracked since 2026-09-07.
What would change the status
The headline verdict is the majority of the decided ratio standards — 3 pass and 4 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30; market cap as stored on 2026-11-18.
Within 3 points of the line
- AAOIFI investments ratio: 0.8pp over
AAOIFI is within 3 points of its line.
The ratios that move with the share price
AAOIFI's debt ratio (2.3% against a 30% line) would only fail if the market cap fell by 92%, to $239.5M.
AAOIFI's investments ratio is $976.4M cash and interest-bearing investments over a market cap of $3.2B (as of 2026-11-18), 30.8% against a 30% line.
It would pass if the market cap rose above $3.3B (+3%), about $18.83 a share against $18.32 implied by the screen's own figures.
AAOIFI would then pass.
At the screen's market cap, it would take $26.6M less cash and interest-bearing investments to clear the line.
AAOIFI would then pass.
Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.
Shariah-compliant alternatives
Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.
| Company | Market cap | Price, day |
|---|---|---|
| VRTXVertex Pharmaceuticals, Inc. | $121.1B | — |
| REGNRegeneron Pharmaceuticals, Inc. | $85.3B | — |
| ARGXArgen X SE - ADR | $64.3B | — |
| ONCBeOne Medicines Ltd. American Depositary Shares | $40.4B | — |
| ALNYAlnylam Pharmaceuticals Inc | $31.6B | — |
A dash means no fresh quote is cached for that symbol; this list does not fetch one.
Funds that hold ACAD
7 of the 208 funds whose filed holdings we currently hold own ACAD shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns ACAD.
You may already own itWidely held U.S. index funds. If you own one, you own ACAD through it. None of them is a Shariah fund; the last column is our look-through of each.
| Fund | ACAD in fund | Fund compliant by weight |
|---|---|---|
| SCHB Schwab U.S. Broad Market ETF | 0.01% | 53% |
| VTI VANGUARD TOTAL STOCK MARKET INDEX FUND | 0.00% | 54% |
| ITOT iShares Core S&P Total U.S. Stock Market ETF | 0.00% | 54% |
| Fund | ACAD in fund | Fund compliant by weight |
|---|---|---|
| ADOCX Alger Dynamic Opportunities Fund | 0.57% | not computed |
| VBK VANGUARD SMALL-CAP GROWTH INDEX FUND | 0.09% | 64% |
| FAD First Trust Multi Cap Growth AlphaDEX Fund | 0.05% | 59% |
| GARUX Goldman Sachs Absolute Return Tracker Fund | 0.01% | not computed |
Sorted by ACAD’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names ACAD once, so a bond is not counted as the shares. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Ken Griffin | Citadel Advisors | $49M | 0.0% | 2026-09-30 |
| David Shaw | D. E. Shaw & Co. | $43M | 0.0% | 2026-09-30 |
| Steven Cohen | Point72 Asset Management | $23M | 0.0% | 2026-09-30 |
| Peter Brown | Renaissance Technologies | $22M | 0.0% | 2026-09-30 |
| Israel Englander | Millennium Management | $17M | 0.0% | 2026-09-30 |
| Ken Fisher | Fisher Asset Management | $14M | 0.0% | 2026-09-30 |
| Paul Tudor Jones | Tudor Investment Corp | $2M | 0.0% | 2026-09-30 |
| John Hussman | Hussman Strategic Advisors | $2M | 0.5% | 2026-09-30 |
| Chuck Royce | Royce & Associates | $2M | 0.0% | 2026-09-30 |
| Ray Dalio | Bridgewater Associates | $1M | 0.0% | 2026-09-30 |
| Joel Greenblatt | Gotham Asset Management | $0M | 0.0% | 2026-09-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 37.60 | NEUTRAL |
| Stochastic %K (14) | 29.10 | NEUTRAL |
| CCI (20) | -94.64 | NEUTRAL |
| Williams %R (14) | -70.90 | NEUTRAL |
| MACD (12,26,9) | -0.07 | SELL |
| ROC (10) | -16.95 | SELL |
| Momentum (10) | -3.64 | SELL |
| EMA (10) | 18.71 | SELL |
| SMA (10) | 18.73 | SELL |
| EMA (20) | 19.32 | SELL |
| SMA (20) | 19.57 | SELL |
| EMA (30) | 19.94 | SELL |
| SMA (30) | 19.58 | SELL |
| EMA (50) | 21.08 | SELL |
| SMA (50) | 21.22 | SELL |
| EMA (100) | 22.57 | SELL |
| SMA (100) | 24.30 | SELL |
| EMA (200) | 23.09 | SELL |
| SMA (200) | 23.23 | SELL |
About Acadia Pharmaceuticals Inc
Healthcare · Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Background via Yahoo Finance — informational, not part of the verdict.
Latest Signal — 2026-11-10
Stop 16.10 Now 17.83 Target 21.00
🟠 NOT YET
The main driver: insider selling on the open market. More negatives than positives right now. The setup isn't ready — check back when the trend or RSI changes.
Scores: 1 bullish / 2 bearish
Weak — low conviction, small size or skip
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 64 |
| ⏰ 4H | BULLISH | 42 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is this a fatwa?
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Why can the standards disagree?
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
How often is this re-screened?
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
Do I need to purify dividends?
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
CLUSTER SELL 0 buys · 5 sells
Recent: Schneyer Mark C. sold 77120 sh @ $29.00 (2026-08-06); Schneyer Mark C. sold 67828 sh @ $29.34 (2026-08-06); Schneyer Mark C. sold 67828 sh @ $29.00 (2026-08-05)
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-11-10 · Asset managers net 914130 (-14454)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.